MicroRNA 155 control of p53 activity is context dependent and mediated by aicda and Socs1

Molecular and Cellular Biology

Volumn 35, Issue 8, 2015, Pages 1329-1340

  Bouamar, Hakim ^a   Jiang, Daifeng ^a   Wang, Long ^a   Lin, An Ping ^a   Ortega, Manoela ^a   Aguiar, Ricardo C T ^a,b,c  

^a University of Texas Health Science Center   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c SOUTH TEXAS VETERANS HEALTH CARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATION INDUCED CYTIDINE DEAMINASE; CYCLIN DEPENDENT KINASE INHIBITOR 1C; INTERLEUKIN 4; LIPOPOLYSACCHARIDE; MICRORNA 155; NUCLEAR PROTEIN; PROTEIN GAMMA H2AX; PROTEIN P15; PROTEIN P16; PROTEIN P21; PROTEIN P53; SMALL INTERFERING RNA; SUPPRESSOR OF CYTOKINE SIGNALING 1; UNCLASSIFIED DRUG; AICDA (ACTIVATION-INDUCED CYTIDINE DEAMINASE); CYTIDINE DEAMINASE; GAMMA-H2AX PROTEIN, MOUSE; HISTONE; MICRORNA; MIRN155 MICRORNA, MOUSE; SOCS1 PROTEIN, MOUSE; SUPPRESSOR OF CYTOKINE SIGNALING;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; B LYMPHOCYTE; CELL AGING; CELL CYCLE ARREST; CELL LOSS; CONTROLLED STUDY; DOUBLE STRANDED DNA BREAK; ELECTROPORATION; GERMINAL CENTER; IMMUNOFLUORESCENCE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STABLE EXPRESSION; ANIMAL; CELL CULTURE; CELL CYCLE CHECKPOINT; CYTOLOGY; FEMALE; GENE DELETION; GENETICS; IMMUNOLOGY; MALE; METABOLISM; RNA INTERFERENCE; UPREGULATION;

MUS;

ANIMALS; APOPTOSIS; B-LYMPHOCYTES; CELL CYCLE CHECKPOINTS; CELLS, CULTURED; CYTIDINE DEAMINASE; DNA BREAKS, DOUBLE-STRANDED; FEMALE; GENE DELETION; GERMINAL CENTER; HISTONES; MALE; MICE; MICRORNAS; RNA INTERFERENCE; RNA, SMALL INTERFERING; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS; TUMOR SUPPRESSOR PROTEIN P53; UP-REGULATION;

EID: 84925426163     PISSN: 02707306     EISSN: 10985549     Source Type: Journal    
DOI: 10.1128/MCB.01446-14     Document Type: Article

References (37)

1. Keim C, Kazadi D, Rothschild G, Basu U. 2013. Regulation of AID, the B-cell genome mutator. Genes Dev 27:1-17. http://dx.doi.org/10.1101/gad.200014.112.
2. Xu Z, Pone EJ, Al-Qahtani A, Park SR, Zan H, Casali P. 2007. Regulation of aicda expression and AID activity: relevance to somatic hypermutation and class switch DNA recombination. Crit Rev Immunol 27:367-397. http://dx.doi.org/10.1615/CritRevImmunol.v27.i4.60.
3. Liu M, Duke JL, Richter DJ, Vinuesa CG, Goodnow CC, Kleinstein SH, Schatz DG. 2008. Two levels of protection for the B cell genome during somatic hypermutation. Nature 451:841-845. http://dx.doi.org/10.1038/nature06547.
4. Phan RT, Saito M, Basso K, Niu H, Dalla-Favera R. 2005. BCL6 interacts with the transcription factor Miz-1 to suppress the cyclin-dependent kinase inhibitor p21 and cell cycle arrest in germinal center B cells. Nat Immunol 6:1054-1060. http://dx.doi.org/10.1038/ni1245.
5. Ranuncolo SM, Polo JM, Dierov J, Singer M, Kuo T, Greally J, Green R, Carroll M, Melnick A. 2007. Bcl-6 mediates the germinal center B cell phenotype and lymphomagenesis through transcriptional repression of the DNA-damage sensor ATR. Nat Immunol 8:705-714. http://dx.doi.org/10.1038/ni1478.
6. Phan RT, Dalla-Favera R. 2004. The BCL6 proto-oncogene suppresses p53 expression in germinal-centre B cells. Nature 432:635-639. http://dx.doi.org/10.1038/nature03147.
7. Frankenberger S, Davari K, Fischer-Burkart S, Bottcher K, Tomi NS, Zimber-Strobl U, Jungnickel B. 2014. Checkpoint kinase 1 negatively regulates somatic hypermutation. Nucleic Acids Res 42:3666-3674. http://dx.doi.org/10.1093/nar/gkt1378.
8. Ramiro AR, Jankovic M, Callen E, Difilippantonio S, Chen HT, McBride KM, Eisenreich TR, Chen J, Dickins RA, Lowe SW, Nussenzweig A, Nussenzweig MC. 2006. Role of genomic instability and p53 in AID-induced c-myc-Igh translocations. Nature 440:105-109. http://dx.doi.org/10.1038/nature04495.
9. Selbach M, Schwanhausser B, Thierfelder N, Fang Z, Khanin R, Rajewsky N. 2008. Widespread changes in protein synthesis induced by micro-RNAs. Nature 455:58-63. http://dx.doi.org/10.1038/nature07228.
10. Baek D, Villen J, Shin C, Camargo FD, Gygi SP, Bartel DP. 2008. The impact of microRNAs on protein output. Nature 455:64-71. http://dx.doi.org/10.1038/nature07242.
11. Costinean S, Zanesi N, Pekarsky Y, Tili E, Volinia S, Heerema N, Croce CM. 2006. Pre-B cell proliferation and lymphoblastic leukemia/highgrade lymphoma in E(mu)-miR155 transgenic mice. Proc Natl Acad Sci U S A 103:7024-7029. http://dx.doi.org/10.1073/pnas.0602266103.
12. Thai TH, Calado DP, Casola S, Ansel KM, Xiao C, Xue Y, Murphy A, Frendewey D, Valenzuela D, Kutok JL, Schmidt-Supprian M, Rajewsky N, Yancopoulos G, Rao A, Rajewsky K. 2007. Regulation of the germinal center response by microRNA-155. Science 316:604-608. http://dx.doi.org/10.1126/science.1141229.
13. Dorsett Y, McBride KM, Jankovic M, Gazumyan A, Thai TH, Robbiani DF, Di Virgilio M, San-Martin BR, Heidkamp G, Schwickert TA, Eisenreich T, Rajewsky K, Nussenzweig MC. 2008. MicroRNA-155 suppresses activation-induced cytidine deaminase-mediated Myc-Igh translocation. Immunity 28:630-638. http://dx.doi.org/10.1016/j.immuni.2008.04.002.
14. Teng G, Hakimpour P, Landgraf P, Rice A, Tuschl T, Casellas R, Papavasiliou FN. 2008. MicroRNA-155 is a negative regulator of activation-induced cytidine deaminase. Immunity 28:621-629. http://dx.doi.org/10.1016/j.immuni.2008.03.015.
15. Huffaker TB, Hu R, Runtsch MC, Bake E, Chen X, Zhao J, Round JL, Baltimore D, O'Connell RM. 2012. Epistasis between microRNAs 155 and 146a during T cell-mediated antitumor immunity. Cell Rep 2:1697-1709. http://dx.doi.org/10.1016/j.celrep.2012.10.025.
16. Basso K, Schneider C, Shen Q, Holmes AB, Setty M, Leslie C, Dalla-Favera R. 2012. BCL6 positively regulates AID and germinal center gene expression via repression of miR-155. J Exp Med 209:2455-2465. http://dx.doi.org/10.1084/jem.20121387.
17. O'Connell RM, Rao DS, Chaudhuri AA, Boldin MP, Taganov KD, Nicoll J, Paquette RL, Baltimore D. 2008. Sustained expression of microRNA-155 in hematopoietic stem cells causes a myeloproliferative disorder. J Exp Med 205:585-594. http://dx.doi.org/10.1084/jem.20072108.
18. Rai D, Kim SW, McKeller MR, Dahia PL, Aguiar RC. 2010. Targeting of SMAD5 links microRNA-155 to the TGF-beta pathway and lymphomagenesis. Proc Natl Acad Sci U S A 107:3111-3116. http://dx.doi.org/10.1073/pnas.0910667107.
19. Jiang D, Aguiar RC. 2014. MicroRNA-155 controls RB phosphorylation in normal and malignant B lymphocytes via the noncanonical TGF-beta1/SMAD5 signaling module. Blood 123:86-93. http://dx.doi.org/10.1182/blood-2013-07-515254.
20. Atkuri KR, Herzenberg LA, Niemi AK, Cowan T. 2007. Importance of culturing primary lymphocytes at physiological oxygen levels. Proc Natl Acad Sci U S A 104:4547-4552. http://dx.doi.org/10.1073/pnas.0611732104.
21. Delhommeau F, Dupont S, Della Valle V, James C, Trannoy S, Masse A, Kosmider O, Le Couedic JP, Robert F, Alberdi A, Lecluse Y, Plo I, Dreyfus FJ, Marzac C, Casadevall N, Lacombe C, Romana SP, Dessen P, Soulier J, Viguie F, Fontenay M, Vainchenker W, Bernard OA. 2009. Mutation in TET2 in myeloid cancers. NEngl J Med 360:2289-2301. http://dx.doi.org/10.1056/NEJMoa0810069.
22. Qin Y, Deng Y, Ricketts CJ, Srikantan S, Wang E, Maher ER, Dahia PL. 2014. The tumor susceptibility gene TMEM127 is mutated in renal cell carcinomas and modulates endolysosomal function. Hum Mol Genet 23:2428-2439. http://dx.doi.org/10.1093/hmg/ddt638.
23. French AP, Mills S, Swarup R, Bennett MJ, Pridmore TP. 2008. Colocalization of fluorescent markers in confocal microscope images of plant cells. Nat Protoc 3:619-628. http://dx.doi.org/10.1038/nprot.2008.31.
24. Bouamar H, Abbas S, Lin AP, Wang L, Jiang D, Holder KN, Kinney MC, Hunicke-Smith S, Aguiar RC. 2013. A capture-sequencing strategy identifies IRF8, EBF1, and APRIL as novel IGH fusion partners in B-cell lymphoma. Blood 122:726-733. http://dx.doi.org/10.1182/blood-2013-04-495804.
25. Calabrese V, Mallette FA, Deschenes-Simard X, Ramanathan S, Gagnon J, Moores A, Ilangumaran S, Ferbeyre G. 2009. SOCS1 links cytokine signaling to p53 and senescence. Mol Cell 36:754-767. http://dx.doi.org/10.1016/j.molcel.2009.09.044.
26. Ortega M, Bhatnagar H, Lin AP, Wang L, Aster JC, Sill H, Aguiar RC. 14 October 2014. A microRNA-mediated regulatory loop modulates NOTCH and MYC oncogenic signals in B- and T-cell malignancies. Leukemia http://dx.doi.org/10.1038/leu.2014.302.
27. Kim SW, Ramasamy K, Bouamar H, Lin AP, Jiang D, Aguiar RC. 2012. MicroRNAs miR-125a and miR-125b constitutively activate the NF-kappaB pathway by targeting the tumor necrosis factor alpha-induced protein 3 (TNFAIP3, A20). Proc Natl Acad Sci U S A 109:7865-7870. http://dx.doi.org/10.1073/pnas.1200081109.
28. Kinner A, Wu W, Staudt C, Iliakis G. 2008. Gamma-H2AX in recognition and signaling of DNA double-strand breaks in the context of chromatin. Nucleic Acids Res 36:5678-5694. http://dx.doi.org/10.1093/nar/gkn550.
29. Pant V, Quintas-Cardama A, Lozano G. 2012. The p53 pathway in hematopoiesis: lessons from mouse models, implications for humans. Blood 120:5118-5127. http://dx.doi.org/10.1182/blood-2012-05-356014.
30. Lu LF, Thai TH, Calado DP, Chaudhry A, Kubo M, Tanaka K, Loeb GB, Lee H, Yoshimura A, Rajewsky K, Rudensky AY. 2009. Foxp3-dependent microRNA155 confers competitive fitness to regulatory T cells by targeting SOCS1 protein. Immunity 30:80-91. http://dx.doi.org/10.1016/j.immuni.2008.11.010.
31. Davey GM, Heath WR, Starr R. 2006. SOCS1: a potent and multifaceted regulator of cytokines and cell-mediated inflammation. Tissue Antigens 67:1-9. http://dx.doi.org/10.1111/j.1399-0039.2005.00532.x.
32. Gasparini P, Lovat F, Fassan M, Casadei L, Cascione L, Jacob NK, Carasi S, Palmieri D, Costinean S, Shapiro CL, Huebner K, Croce CM. 2014. Protective role of miR-155 in breast cancer through RAD51 targeting impairs homologous recombination after irradiation. Proc Natl Acad Sci U S A 111:4536-4541. http://dx.doi.org/10.1073/pnas.1402604111.
33. Mottok A, Renne C, Seifert M, Oppermann E, Bechstein W, Hansmann ML, Kuppers R, Brauninger A. 2009. Inactivating SOCS1 mutations are caused by aberrant somatic hypermutation and restricted to a subset of B-cell lymphoma entities. Blood 114:4503-4506. http://dx.doi.org/10.1182/blood-2009-06-225839.
34. Young KH, Leroy K, Moller MB, Colleoni GW, Sanchez-Beato M, Kerbauy FR, Haioun C, Eickhoff JC, Young AH, Gaulard P, Piris MA, Oberley TD, Rehrauer WM, Kahl BS, Malter JS, Campo E, Delabie J, Gascoyne RD, Rosenwald A, Rimsza L, Huang J, Braziel RM, Jaffe ES, Wilson WH, Staudt LM, Vose JM, Chan WC, Weisenburger DD, Greiner TC. 2008. Structural profiles of TP53 gene mutations predict clinical outcome in diffuse large B-cell lymphoma: an international collaborative study. Blood 112:3088-3098. http://dx.doi.org/10.1182/blood-2008-01-129783.
35. O'Connell RM, Chaudhuri AA, Rao DS, Baltimore D. 2009. Inositol phosphatase SHIP1 is a primary target of miR-155. Proc Natl Acad Sci U S A 106:7113-7118. http://dx.doi.org/10.1073/pnas.0902636106.
36. Loeb GB, Khan AA, Canner D, Hiatt JB, Shendure J, Darnell RB, Leslie CS, Rudensky AY. 2012. Transcriptome-wide miR-155 binding map reveals widespread noncanonical microRNA targeting. Mol Cell 48:760-770. http://dx.doi.org/10.1016/j.molcel.2012.10.002.
37. Jiang S, Zhang HW, Lu MH, He XH, Li Y, Gu H, Liu MF, Wang ED. 2010. MicroRNA-155 functions as an OncomiR in breast cancer by targeting the suppressor of cytokine signaling 1 gene. Cancer Res 70:3119-3127. http://dx.doi.org/10.1158/0008-5472.CAN-09-4250.